Zhaoke Ophthalmology's melphalan receives US FDA orphan drug status

Zhaoke Ophthalmology Limited announced its melphalan formulation received Orphan Drug Designation from the US FDA for pediatric retinoblastoma, a rare eye cancer.

Successful development and approval would grant the company seven years of US market exclusivity, preventing FDA approval of other melphalan-based products for this indication.